Ivax ( IVX) said it expects to earn 20 cents a share for the third quarter, which includes 4 cents in merger-related expenses and other costs. The Miami-based company issued the earnings prediction Monday in advance of a formal earnings announcement on Nov. 8 because it says "current analysts' estimates do not take these items into account." The Wall Street consensus is for earnings of 23 cents a share for the three months ended Sept. 30, according to Thomson First Call, whose estimates exclude one-time items. In addition to expenses tied to the pending merger with Teva Pharmaceutical Industries ( TEVA), Ivax said the consensus doesn't reflect EPS dilution from additional shares outstanding or considered outstanding because of options and convertible notes. Shareholders of Ivax and Teva are scheduled to vote on the deal in separate special meetings on Oct. 27. Teva made
a $7.4 billion bid for Ivax in late July. Earlier this month, the Federal Trade Commission asked for additional information from the companies. They say the deal should close in late 2005 or early 2006.